Request Demo
Chugai In-Licenses Anti-TL1A Antibody RG6631 for the Intractable Diseases Ulcerative Colitis and Crohn’s Disease
Phase 2License out/inClinical Result
All html pdf doc xls ppt match recent 10 20 30 none small medium large Home About Chugai News Chugai In-Licenses Anti-TL1A Antibody RG6631 for the Intractable Diseases Ulcerative Colitis and Crohn’s Disease Chugai obtained exclusive development and marketing rights in Japan for RG6631, an anti-TL1A antibody under development for ulcerative colitis and Crohn’s disease, from Roche. With its novel mode of action targeting suppression of inflammation and fibrosis by inhibiting TL1A, RG6631 could offer a promising new therapy for people suffering from ulcerative colitis and Crohn’s disease, which are characterized by low rates of remission induction and maintenance, and has the potential to be applied in multiple other diseases. TOKYO, August 7, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that it has concluded a license agreement with F. Hoffmann-La Roche Ltd (hereafter “Roche”) [Head Office: Basel, Switzerland. Thomas Schinecker] for RG6631, the anti-TL1A antibody, currently in development for ulcerative colitis and Crohn’s disease. Under the license agreement between Roche and Chugai, Chugai obtained exclusive rights for the development and marketing of RG6631 in Japan. Roche will receive an upfront fee and milestone payments. “Ulcerative colitis and Crohn’s disease are intractable conditions characterized by cycles of remission and relapse. The recurring symptoms such as diarrhea and abdominal pain often restrict daily life, requiring long-term hospital visits, and the risk of developing colon cancer increases as the disease progresses1. In addition, treatment methods to maintain remission have not been sufficiently established, and there remains a significant unmet need. Chugai will work closely with Roche to bring RG6631 to patients with Ulcerative colitis and Crohn’s disease as soon as possible,” said Chugai’s President and CEO, Dr. Osamu Okuda. RG6631 is a potential first-in-class therapy targeting TL1A, is expected to demonstrate high efficacy by simultaneously suppressing inflammation and fibrosis, and has the potential to be applied in multiple other diseases. In the global phase IIb study (TUSCANY-2)2 in patients with moderate to severe ulcerative colitis, treatment with RG6631 showed improvement in multiple endpoints including clinical remission in both the induction and maintenance periods. Roche plans to initiate a phase III study by the end of 2024. The phase II study is ongoing for moderate to severe Crohn’s disease. Chugai will continue to effectively utilize the research and development resources of the Roche Group to find innovative new drugs so as to satisfy unmet medical needs. About Ulcerative Colitis and Crohn’s Disease Ulcerative colitis and Crohn’s disease are inflammatory bowel diseases, which refer to chronic or relapsing-remitting inflammatory disorders of the intestinal tract. Symptoms include abdominal pain, frequent bowel movements, diarrhea, weight loss and fatigue4,5. Approximately 80% of patients do not achieve sustained remission6, with cycles of relapse and remission being common3. Loss of response to medications can also occur over time, and there remains a need for new therapies, particularly for small bowel and perianal disease7. About Ulcerative Colitis Ulcerative colitis has a peak onset in the 20s and is a condition in which erosions and ulcers form in the mucosa (innermost layer) of the large intestine. Lesions tend to spread continuously from the rectum and ascend orally, extending to the entire colon at maximum1. It is one of the designated intractable diseases in Japan (designated intractable disease 97), and the number of medical recipient certificate holders for this disease was 141,387 at the end of year 20228. About Crohn’s Disease Crohn’s disease is mainly seen in younger age groups and is characterized by discontinuous lesions (the presence of normal areas between lesions). Inflammation and ulcers (mucosal defects) primarily affect the small and large intestines, with the terminal ileum being a common site, but can occur in any part of the digestive tract from the mouth to the anus1. It is one of the designated intractable diseases in Japan (designated intractable disease 96), and the number of medical recipient certificate holders for this disease was 50,184 at the end of year 20228. Sources Partially modified from Japan Intractable Diseases Information Center. Available from: https://www.nanbyou.or.jp/. Accessed June 2024. (Japanese only) Press release by Roivant issued on June 22, 2023 https://investor.roivant.com/news-releases/news-release-details/roivant-reports-chronic-period-data-rvt-3101-tuscany-2-phase-2b/ The Japanese Gastroenterological Association Guidelines. Available from: https://www.jsge.or.jp/committees/guideline/guideline/ibd.html. Accessed June 2024. (Japanese only) Ungaro R, et al. Ulcerative colitis. Lancet. 2017; 389(10080):1756-70. Torres J, et al. Crohn’s disease. Lancet. 2017; 389:1741-55. Sandborn WJ. The Present and Future of inflammatory bowel disease Treatment. Gastroenterol Hepatol. 2016; 12:438–41. Renisch W. et. al., Inflamm Bowel Dis. 2012 Feb;18(2):201-11., Feagan BG et.al. N Engl J Med. 2013 Aug 22;369(8):699-710., Amiot A. et.al. Therap Adv Gastroenterol. 2015; 8(2): 66–82. Portal Site of Official Statistics of Japan website (https://www.e-stat.go.jp/). Report on Public Health Administration and Services FY2022, Accessed July 2024. (in Japanese only) [PDF 302KB] Contact: For Media Chugai Pharmaceutical Co., Ltd. Media Relations Group, Corporate Communications Dept., Hideki Sato Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp For Investors Chugai Pharmaceutical Co., Ltd. Investor Relations Group, Corporate Communications Dept., Takayuki Sakurai Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp Back Home About Chugai News Chugai In-Licenses Anti-TL1A Antibody RG6631 for the Intractable Diseases Ulcerative Colitis and Crohn’s Disease About Chugai Message from the CEO Chugai’s Five Strengths Company Outline Our Vision Our Strategy History of Chugai Pharmaceutical Chugai Group R&D Digital Transformation "CHUGAI DIGITAL" Videos & Advertisements Press Room News Media Conference Partnering To our suppliers Investor Relations Management Policy Financial Results Reports & Downloads Shareholder Information Corporate Governance ESG at Chugai Main Products / Development Pipeline See how Chugai compares to other companies Strategic Alliance with Roche Chugai’s Five Strengths Events & Presentations Contacts & Information FAQs Recruitment Chugai Recruiting Site Sustainability Basic Policy (Creation of Shared Value) Sustainability and Business Strategy Sustainable Patient-Centric Healthcare Global Health Human Resources and Diversity & Inclusion Ethics and Compliance Supply Chain Management Human Rights Social Contribution Global Environment Health and Productivity Management Governance External Evaluations Activity Reports Data Chugai's Transparency Guidelines You are now moving to an external website. Access the link Our use of cookiesWe use cookies to improve your experience on our website (www.chugai-pharm.co.jp), to provide social media features and to analyze our traffic. By clicking “Accept Cookies”, you consent to the use of all cookies. For more information, configuration and to withdraw your consent, please click “Cookie Settings”. You can manage the settings at any time from the “Cookie Policy” link at the bottom of each page.Cookie Policy Privacy Preference CenterWhen you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information Manage Consent PreferencesStrictly Necessary CookiesAlways ActiveThese cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information. Performance Cookies Performance Cookies These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. Functional Cookies Functional Cookies These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly. Targeting Cookies Targeting Cookies These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising. Cookie List checkbox label label Consent Leg.Interest checkbox label label checkbox label label checkbox label label
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!